Nanoform Finland Plc
November 16, 2020
11:00 a.m. Finnish time
Invitation to presentation of Nanoform’s Q3 Report on November 27
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, will publish its interim report for the third quarter of 2020 on November 27, 2020, at 08.00 a.m. Helsinki time (07.00 a.m. Stockholm time).
The company will hold a conference call and an online presentation on the same day at 15.00 p.m. Helsinki time (14.00 p.m. Stockholm time). Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström, CCO Christian Jones and CBO Gonçalo Andrade. The presentation will be delivered in English.
The presentation will be broadcast live as a webcast available at: https://financialhearings.com/event/13383
Teleconference dial-in numbers:
United Kingdom: +443333009263
United States: +18332498407
For further information, please contact:
Henri von Haartman, Director of Investor Relations
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming services. The Company’s patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform’s unique technology provides novel opportunities in many value-enhancing drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806. For more information please visit http://www.nanoform.com